三阴性乳腺癌预后生物标志物的研究进展

Triple-negative breast cancer(TNBC)is a molecular subtype of breast cancer characterized by the lack of expression of estrogen receptor(ER), progesterone receptor(PR)and HER-2, which becomes one difficult trouble of breast cancer clinical treatment because of the characters of low degree of differentiation, high heterogeneity, highly aggressive behaviour, high recurrence frequency, poor prognosis, and lack of targeted therapies.With the rapid development of molecular biology in the recent years, molecular biomarkers have been found associated with prognosis in patients with TNBC, which makes it possible to predict cancer patients\'survival precisely and effectively. This review summarized those new developments of biomarkers on the prognosis of TNBC and the targeted therapies.